Venous Thromboembolism awareness~ Roger VL, Go AS, Lloyd-Jones DM, et al. Heart disease and stroke statistics—2012 update: A report from the American Heart Association. Circulation. 2012;125(1):e2-e220. Heit J, O’Fallon W, Petterson T, Lohse C, Silverstein M, Mohr D, Melton L. Relative impact of risk factors for deep vein thrombosis and pulmonary embolism: a population-based study. Arch Intern Med. 2002; 162: 1245–1248. Forster AJ, et al: Adverse drug events occurring following hospital discharge. Journal of General Internal Medicine, April 2005;20(4):317-23 Medicare Payment Advisory Commission, Report to the Congress: Reforming the Delivery System, Washington, D.C.: MedPAC, June 2008 Bratzler, Dale W. “Development of National Performance Measures on the Prevention and Treatment of Venous Thromboembolism.” Journal of Thrombosis And Thrombolysis 29, no. 2 (2010): 148-54. Heit JA. The epidemiology of venous thromboembolism in the community. Arterioscler Thromb Vasc Biol. 2008;28(3):370-372.
Statins could hold the key to eradicating one of the most preventable causes of hospital deaths after researchers uncovered a new role for the cholesterol-lowering pill. The medication, commonly used to prevent heart attacks, reduces the threat of a condition affecting millions globally called venous thromboembolism (VTE), where blood clots form in the vein in the lungs or in limbs, by between 15 and 25%. The conclusion was made following a thorough analysis of 36 studies involving >3.2 million people as part of new research published in The Lancet Haematology.
It was supported by NIHR Collaboration for Leadership for Applied Health Research and Care (CLAHRC) East Midlands and the NIHR Leicester-Loughborough Diet, Lifestyle and Physical Activity Biomedical Research Unit. The results of the summary compiled by researchers from Leicester Diabetes Centre and the University of Bristol provide an “extensive body of evidence on the clinical benefit of statin in the occurrence of VTE.”
The finding could potentially lead to new guidelines and an expansion of the use of treatment, which is already established in cardiovascular disease prevention. Co-investigator Professor Kamlesh Khunti, Professor of Primary Care Diabetes & Vascular Medicine at the University of Leicester, Director NIHR CLAHRC East Midlands and Co-Director of the Leicester Diabetes Centre, said: “These findings underscore a potential beneficial role of statin therapy on VTE in addition to its established role in cardiovascular disease prevention.”
Lead researcher Dr Setor Kunutsor, University of Bristol’s Musculoskeletal Research Unit, added: “Currently, statins are only approved for lipid lowering in the primary and secondary prevention of cardiovascular disease. “But they have shown great promise beyond their established lipid-lowering effects and these include potential beneficial impact on multiple disease conditions.
http://www.alphagalileo.org/ViewItem.aspx?ItemId=171777&CultureCode=en
http://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(16)30184-3/abstract
Recent Comments